StockVS

NASDAQ · Biotechnology · USD

Dyadic International, Inc. (DYAI) Stock Analysis

Dyadic International, Inc. (DYAI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

DYAI

$0.52

+$0.02 (+4.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DYAI with… →

DYAI Key Statistics

As of Sep 4, 2026
Trading
Open
$0.50
Previous Close
$0.50
Day's Range
0.48–0.53
52-Week Range
0.48–1.60
Volume
126.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.96
Valuation
Market Cap
$20.84M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.48
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.22
Financials (FY)
Revenue (FY)
$1.23M−64.74%
Net Income (FY)
−$7.36M
Profit marginThe share of revenue left as profit after all costs and taxes.
−200.46%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
40.06M
1-Year Return
−45.83%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
216.74K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DYAI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.68%
2025−46.29%
2024+8.70%
2023+30.89%
2022−72.79%
2021−15.99%
2020+3.86%
2019+174.07%
2018+35.97%
2017−16.27%
2016 (partial year)+18.57%

As of September 4, 2026.

DYAI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.23M−$7.36M−597.6%
2024$3.50M−$5.81M−166.2%
2023$2.90M−$6.80M−234.4%
2022$2.93M−$9.74M−332.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.23M−$1.09M−$7.15M−$7.36M−597.6%
2024$3.50M$2.30M−$5.88M−$5.81M−166.2%
2023$2.90M$922.96K−$8.19M−$6.80M−234.4%
2022$2.93M$807.11K−$10.12M−$9.74M−332.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DYAI Valuation vs Biotechnology Median

Median of 656 stocks
MetricDYAIBiotechnology medianvs median
P/S ratio5.4815.2664% below
Profit margin−200.46%0.00%200.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Dyadic International, Inc. (DYAI) at $20.84M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 5 employees.

The most recent close on file for DYAI is $0.52, dated September 4, 2026. That is +$0.02 (+4.00%) against the previous close. Over the past 52 weeks the price has ranged from $0.48 to $1.60. The latest close sits 8.33% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.23M. Against the prior fiscal year total of $3.50M, that is a change of −64.74%. The same year closed with a net loss of $7.36M. Profit margin runs at −200.46%. That is 200.5 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.22.

Across the 4 fiscal years on file, revenue moves from $2.93M in 2022 to $1.23M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 5.48 times revenue. On price-to-sales that is 64.09% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.96. Daily returns over the trailing 10 years annualize to a volatility of 71.58%. Over the trailing twelve months the price has returned −45.83%. Measured over 10 years, that is −9.62% a year compounded.

Growth & Income

The record shows no dividend for DYAI.

2026 is still running; the price is −44.68% year to date. The strongest complete calendar year on file is 2019 at +174.07%; the weakest is 2022 at −72.79%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Dyadic International, Inc. (DYAI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Dyadic International, Inc. DYAI $20.84M
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Dyadic International, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

View all Biotechnology stocks →

Popular Healthcare Stocks

View all Healthcare stocks →

About Dyadic International, Inc.

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Visit website →